Single User License
INR 170050
Site License
INR 340100
Corporate User License
INR 510150

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Non-Small Cell Lung Cancer-Pipeline Review, H1 2015

Non-Small Cell Lung Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Non-Small Cell Lung Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Non-Small Cell Lung Cancer-Pipeline Review, H1 2015', provides an overview of the Non-Small Cell Lung Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Non-Small Cell Lung Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 12

Non-Small Cell Lung Cancer Overview 13

Therapeutics Development 14

Non-Small Cell Lung Cancer-Therapeutics under Development by Companies 16

Non-Small Cell Lung Cancer-Therapeutics under Investigation by Universities/Institutes 35

Non-Small Cell Lung Cancer-Pipeline Products Glance 39

Non-Small Cell Lung Cancer-Products under Development by Companies 43

Non-Small Cell Lung Cancer-Products under Investigation by Universities/Institutes 75

Non-Small Cell Lung Cancer-Companies Involved in Therapeutics Development 79

Non-Small Cell Lung Cancer-Therapeutics Assessment 302

Drug Profiles 344

Non-Small Cell Lung Cancer-Recent Pipeline Updates 1194

Non-Small Cell Lung Cancer-Dormant Projects 1700

Non-Small Cell Lung Cancer-Discontinued Products 1724

Non-Small Cell Lung Cancer-Product Development Milestones 1735

Appendix 1744

List of Tables

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2015 63

Number of Products under Development for Non-Small Cell Lung Cancer-Comparative Analysis, H1 2015 64

Number of Products under Development by Companies, H1 2015 66

Number of Products under Development by Companies, H1 2015 (Contd..1) 67

Number of Products under Development by Companies, H1 2015 (Contd..2) 68

Number of Products under Development by Companies, H1 2015 (Contd..3) 69

Number of Products under Development by Companies, H1 2015 (Contd..4) 70

Number of Products under Development by Companies, H1 2015 (Contd..5) 71

Number of Products under Development by Companies, H1 2015 (Contd..6) 72

Number of Products under Development by Companies, H1 2015 (Contd..7) 73

Number of Products under Development by Companies, H1 2015 (Contd..8) 74

Number of Products under Development by Companies, H1 2015 (Contd..9) 75

Number of Products under Development by Companies, H1 2015 (Contd..10) 76

Number of Products under Development by Companies, H1 2015 (Contd..11) 77

Number of Products under Development by Companies, H1 2015 (Contd..12) 78

Number of Products under Development by Companies, H1 2015 (Contd..13) 79

Number of Products under Development by Companies, H1 2015 (Contd..14) 80

Number of Products under Development by Companies, H1 2015 (Contd..15) 81

Number of Products under Development by Companies, H1 2015 (Contd..16) 82

Number of Products under Development by Companies, H1 2015 (Contd..17) 83

Number of Products under Investigation by Universities/Institutes, H1 2015 85

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 86

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 87

Comparative Analysis by Late Stage Development, H1 2015 88

Comparative Analysis by Clinical Stage Development, H1 2015 89

Comparative Analysis by Early Stage Development, H1 2015 90

Comparative Analysis by Unknown Stage Development, H1 2015 91

Products under Development by Companies, H1 2015 92

Products under Development by Companies, H1 2015 (Contd..1) 93

Products under Development by Companies, H1 2015 (Contd..2) 94

Products under Development by Companies, H1 2015 (Contd..3) 95

Products under Development by Companies, H1 2015 (Contd..4) 96

Products under Development by Companies, H1 2015 (Contd..5) 97

Products under Development by Companies, H1 2015 (Contd..6) 98

Products under Development by Companies, H1 2015 (Contd..7) 99

Products under Development by Companies, H1 2015 (Contd..8) 100

Products under Development by Companies, H1 2015 (Contd..9) 101

Products under Development by Companies, H1 2015 (Contd..10) 102

Products under Development by Companies, H1 2015 (Contd..11) 103

Products under Development by Companies, H1 2015 (Contd..12) 104

Products under Development by Companies, H1 2015 (Contd..13) 105

Products under Development by Companies, H1 2015 (Contd..14) 106

Products under Development by Companies, H1 2015 (Contd..15) 107

Products under Development by Companies, H1 2015 (Contd..16) 108

Products under Development by Companies, H1 2015 (Contd..17) 109

Products under Development by Companies, H1 2015 (Contd..18) 110

Products under Development by Companies, H1 2015 (Contd..19) 111

Products under Development by Companies, H1 2015 (Contd..20) 112

Products under Development by Companies, H1 2015 (Contd..21) 113

Products under Development by Companies, H1 2015 (Contd..22) 114

Products under Development by Companies, H1 2015 (Contd..23) 115

Products under Development by Companies, H1 2015 (Contd..24) 116

Products under Development by Companies, H1 2015 (Contd..25) 117

Products under Development by Companies, H1 2015 (Contd..26) 118

Products under Development by Companies, H1 2015 (Contd..27) 119

Products under Development by Companies, H1 2015 (Contd..28) 120

Products under Development by Companies, H1 2015 (Contd..29) 121

Products under Development by Companies, H1 2015 (Contd..30) 122

Products under Development by Companies, H1 2015 (Contd..31) 123

Products under Investigation by Universities/Institutes, H1 2015 124

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 125

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 126

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 127

Non-Small Cell Lung Cancer-Pipeline by 4SC AG, H1 2015 128

Non-Small Cell Lung Cancer-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 129

Non-Small Cell Lung Cancer-Pipeline by AB Science, H1 2015 130

Non-Small Cell Lung Cancer-Pipeline by AbbVie Inc., H1 2015 131

Non-Small Cell Lung Cancer-Pipeline by ACEA Biosciences, Inc., H1 2015 132

Non-Small Cell Lung Cancer-Pipeline by Adaptimmune Limited, H1 2015 133

Non-Small Cell Lung Cancer-Pipeline by Advanced Cancer Therapeutics, H1 2015 134

Non-Small Cell Lung Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2015 135

Non-Small Cell Lung Cancer-Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 136

Non-Small Cell Lung Cancer-Pipeline by Allinky Biopharma, H1 2015 137

Non-Small Cell Lung Cancer-Pipeline by Altor BioScience Corporation, H1 2015 138

Non-Small Cell Lung Cancer-Pipeline by Ambryx Biotechnology, Inc., H1 2015 139

Non-Small Cell Lung Cancer-Pipeline by Amgen Inc., H1 2015 140

Non-Small Cell Lung Cancer-Pipeline by AndroScience Corporation, H1 2015 141

Non-Small Cell Lung Cancer-Pipeline by Arch Biopartners, Inc., H1 2015 142

Non-Small Cell Lung Cancer-Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 143

Non-Small Cell Lung Cancer-Pipeline by Arog Pharmaceuticals, Inc., H1 2015 144

Non-Small Cell Lung Cancer-Pipeline by ArQule, Inc., H1 2015 145

Non-Small Cell Lung Cancer-Pipeline by Array BioPharma Inc., H1 2015 146

Non-Small Cell Lung Cancer-Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 147

Non-Small Cell Lung Cancer-Pipeline by Ascenta Therapeutics, Inc., H1 2015 148

Non-Small Cell Lung Cancer-Pipeline by Astellas Pharma Inc., H1 2015 149

Non-Small Cell Lung Cancer-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 150

Non-Small Cell Lung Cancer-Pipeline by AstraZeneca Plc, H1 2015 151

Non-Small Cell Lung Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 152

Non-Small Cell Lung Cancer-Pipeline by Axelar AB, H1 2015 153

Non-Small Cell Lung Cancer-Pipeline by Azaya Therapeutics Incorporated, H1 2015 154

Non-Small Cell Lung Cancer-Pipeline by Basilea Pharmaceutica AG, H1 2015 155

Non-Small Cell Lung Cancer-Pipeline by Bayer AG, H1 2015 156

Non-Small Cell Lung Cancer-Pipeline by Benitec Biopharma Limited, H1 2015 157

Non-Small Cell Lung Cancer-Pipeline by BerGenBio AS, H1 2015 158

Non-Small Cell Lung Cancer-Pipeline by Beta Pharma, Inc., H1 2015 159

Non-Small Cell Lung Cancer-Pipeline by BIND Therapeutics, Inc., H1 2015 160

Non-Small Cell Lung Cancer-Pipeline by BIOCAD, H1 2015 161

Non-Small Cell Lung Cancer-Pipeline by BioCancell Ltd, H1 2015 162

Non-Small Cell Lung Cancer-Pipeline by BioLineRx, Ltd., H1 2015 163

Non-Small Cell Lung Cancer-Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2015 164

Non-Small Cell Lung Cancer-Pipeline by Biothera, Inc., H1 2015 165

Non-Small Cell Lung Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 166

Non-Small Cell Lung Cancer-Pipeline by Boston Biomedical, Inc., H1 2015 167

Non-Small Cell Lung Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 168

Non-Small Cell Lung Cancer-Pipeline by Calithera Biosciences, Inc., H1 2015 169

Non-Small Cell Lung Cancer-Pipeline by CanBas Co., Ltd., H1 2015 170

Non-Small Cell Lung Cancer-Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 171

Non-Small Cell Lung Cancer-Pipeline by CASI Pharmaceuticals Inc., H1 2015 172

Non-Small Cell Lung Cancer-Pipeline by cCAM Biotherapeutics Ltd., H1 2015 173

Non-Small Cell Lung Cancer-Pipeline by Celgene Corporation, H1 2015 174

Non-Small Cell Lung Cancer-Pipeline by CellAct Pharma GmbH, H1 2015 175

Non-Small Cell Lung Cancer-Pipeline by Celldex Therapeutics, Inc., H1 2015 176

Non-Small Cell Lung Cancer-Pipeline by Cellectar Biosciences, Inc., H1 2015 177

Non-Small Cell Lung Cancer-Pipeline by Cellectis S.A., H1 2015 178

Non-Small Cell Lung Cancer-Pipeline by Cellmid Limited, H1 2015 179

Non-Small Cell Lung Cancer-Pipeline by Celltrion, Inc., H1 2015 180

Non-Small Cell Lung Cancer-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 181

Non-Small Cell Lung Cancer-Pipeline by Centrose Llc, H1 2015 182

Non-Small Cell Lung Cancer-Pipeline by Chipscreen Biosciences Ltd, H1 2015 183

Non-Small Cell Lung Cancer-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 184

Non-Small Cell Lung Cancer-Pipeline by Clovis Oncology, Inc., H1 2015 185

Non-Small Cell Lung Cancer-Pipeline by Conkwest, Inc., H1 2015 186

Non-Small Cell Lung Cancer-Pipeline by Corcept Therapeutics Incorporated, H1 2015 187

Non-Small Cell Lung Cancer-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 188

Non-Small Cell Lung Cancer-Pipeline by Critical Outcome Technologies Inc., H1 2015 189

Non-Small Cell Lung Cancer-Pipeline by CTI BioPharma Corp., H1 2015 190

Non-Small Cell Lung Cancer-Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 191

Non-Small Cell Lung Cancer-Pipeline by CureVac GmbH, H1 2015 192

Non-Small Cell Lung Cancer-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 193

Non-Small Cell Lung Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 194

Non-Small Cell Lung Cancer-Pipeline by DanDrit Biotech A/S, H1 2015 195

Non-Small Cell Lung Cancer-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 196

Non-Small Cell Lung Cancer-Pipeline by DEKK-TEC, Inc., H1 2015 197

Non-Small Cell Lung Cancer-Pipeline by DiNonA Inc., H1 2015 198

Non-Small Cell Lung Cancer-Pipeline by Domainex Limited, H1 2015 199

Non-Small Cell Lung Cancer-Pipeline by DormaTarg, Inc., H1 2015 200

Non-Small Cell Lung Cancer-Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 201

Non-Small Cell Lung Cancer-Pipeline by Eisai Co., Ltd., H1 2015 202

Non-Small Cell Lung Cancer-Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 203

Non-Small Cell Lung Cancer-Pipeline by Eli Lilly and Company, H1 2015 204

Non-Small Cell Lung Cancer-Pipeline by Endocyte, Inc., H1 2015 205

Non-Small Cell Lung Cancer-Pipeline by EnGeneIC Ltd, H1 2015 206

Non-Small Cell Lung Cancer-Pipeline by EntreChem, S.L., H1 2015 207

Non-Small Cell Lung Cancer-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 208

Non-Small Cell Lung Cancer-Pipeline by Eudendron S.r.l., H1 2015 209

Non-Small Cell Lung Cancer-Pipeline by Exelixis, Inc., H1 2015 210

Non-Small Cell Lung Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 211

Non-Small Cell Lung Cancer-Pipeline by Five Prime Therapeutics, Inc., H1 2015 212

Non-Small Cell Lung Cancer-Pipeline by Fortress Biotech, Inc., H1 2015 213

Non-Small Cell Lung Cancer-Pipeline by Ganymed Pharmaceuticals AG, H1 2015 214

Non-Small Cell Lung Cancer-Pipeline by GeneFrontier Corporation, H1 2015 215

Non-Small Cell Lung Cancer-Pipeline by Genelux Corporation, H1 2015 216

Non-Small Cell Lung Cancer-Pipeline by Genentech, Inc., H1 2015 217

Non-Small Cell Lung Cancer-Pipeline by Genmab A/S, H1 2015 218

Non-Small Cell Lung Cancer-Pipeline by Genor BioPharma Co., Ltd., H1 2015 219

Non-Small Cell Lung Cancer-Pipeline by Genosco, H1 2015 220

Non-Small Cell Lung Cancer-Pipeline by Gilead Sciences, Inc., H1 2015 221

Non-Small Cell Lung Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 222

Non-Small Cell Lung Cancer-Pipeline by Globeimmune, Inc., H1 2015 223

Non-Small Cell Lung Cancer-Pipeline by GlycaNova Norway AS, H1 2015 224

Non-Small Cell Lung Cancer-Pipeline by Glycotope GmbH, H1 2015 225

Non-Small Cell Lung Cancer-Pipeline by Golden Biotechnology Corp., H1 2015 226

Non-Small Cell Lung Cancer-Pipeline by Halozyme Therapeutics, Inc., H1 2015 227

Non-Small Cell Lung Cancer-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 228

Non-Small Cell Lung Cancer-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 229

Non-Small Cell Lung Cancer-Pipeline by Heat Biologics, Inc., H1 2015 230

Non-Small Cell Lung Cancer-Pipeline by HEC Pharm Co., Ltd., H1 2015 231

Non-Small Cell Lung Cancer-Pipeline by Helix BioPharma Corp., H1 2015 232

Non-Small Cell Lung Cancer-Pipeline by Hospira, Inc., H1 2015 233

Non-Small Cell Lung Cancer-Pipeline by Humanetics Corporation, H1 2015 234

Non-Small Cell Lung Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 235

Non-Small Cell Lung Cancer-Pipeline by Ignyta, Inc., H1 2015 236

Non-Small Cell Lung Cancer-Pipeline by Immune Design Corp., H1 2015 237

Non-Small Cell Lung Cancer-Pipeline by Immune Pharmaceuticals Inc., H1 2015 238

Non-Small Cell Lung Cancer-Pipeline by ImmunGene, Inc., H1 2015 239

Non-Small Cell Lung Cancer-Pipeline by ImmunoFrontier, Inc., H1 2015 240

Non-Small Cell Lung Cancer-Pipeline by ImmunoGen, Inc., H1 2015 241

Non-Small Cell Lung Cancer-Pipeline by Immunome Inc., H1 2015 242

Non-Small Cell Lung Cancer-Pipeline by Immunomedics, Inc., H1 2015 243

Non-Small Cell Lung Cancer-Pipeline by Incanthera Ltd., H1 2015 244

Non-Small Cell Lung Cancer-Pipeline by Incuron, LLC, H1 2015 245

Non-Small Cell Lung Cancer-Pipeline by Incyte Corporation, H1 2015 246

Non-Small Cell Lung Cancer-Pipeline by Intezyne, Inc, H1 2015 247

Non-Small Cell Lung Cancer-Pipeline by Io Therapeutics, Inc., H1 2015 248

Non-Small Cell Lung Cancer-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 249

Non-Small Cell Lung Cancer-Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 250

Non-Small Cell Lung Cancer-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 251

Non-Small Cell Lung Cancer-Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2015 252

Non-Small Cell Lung Cancer-Pipeline by Johnson & Johnson, H1 2015 253

Non-Small Cell Lung Cancer-Pipeline by Juno Therapeutics Inc., H1 2015 254

Non-Small Cell Lung Cancer-Pipeline by Kadmon Corporation, LLC, H1 2015 255

Non-Small Cell Lung Cancer-Pipeline by KAEL-GemVax Co., Ltd., H1 2015 256

Non-Small Cell Lung Cancer-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 257

Non-Small Cell Lung Cancer-Pipeline by Loxo Oncology, Inc., H1 2015 258

Non-Small Cell Lung Cancer-Pipeline by Mabion SA, H1 2015 259

Non-Small Cell Lung Cancer-Pipeline by MacroGenics, Inc., H1 2015 260

Non-Small Cell Lung Cancer-Pipeline by Mebiopharm Co., Ltd., H1 2015 261

Non-Small Cell Lung Cancer-Pipeline by MedImmune, LLC, H1 2015 262

Non-Small Cell Lung Cancer-Pipeline by Merck & Co., Inc., H1 2015 263

Non-Small Cell Lung Cancer-Pipeline by Merck KGaA, H1 2015 264

Non-Small Cell Lung Cancer-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 265

Non-Small Cell Lung Cancer-Pipeline by Mersana Therapeutics, Inc., H1 2015 266

Non-Small Cell Lung Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 267

Non-Small Cell Lung Cancer-Pipeline by Mirati Therapeutics Inc., H1 2015 268

Non-Small Cell Lung Cancer-Pipeline by Mirna Therapeutics, Inc., H1 2015 269

Non-Small Cell Lung Cancer-Pipeline by MolMed S.p.A., H1 2015 270

Non-Small Cell Lung Cancer-Pipeline by Morphotek, Inc., H1 2015 271

Non-Small Cell Lung Cancer-Pipeline by NanoCarrier Co., Ltd., H1 2015 272

Non-Small Cell Lung Cancer-Pipeline by Natco Pharma Limited, H1 2015 273

Non-Small Cell Lung Cancer-Pipeline by Nektar Therapeutics, H1 2015 274

Non-Small Cell Lung Cancer-Pipeline by NeoPharm Co., Ltd., H1 2015 275

Non-Small Cell Lung Cancer-Pipeline by NewLink Genetics Corporation, H1 2015 276

Non-Small Cell Lung Cancer-Pipeline by Nimbus Therapeutics, LLC, H1 2015 277

Non-Small Cell Lung Cancer-Pipeline by Novartis AG, H1 2015 278

Non-Small Cell Lung Cancer-Pipeline by NuCana BioMed Limited, H1 2015 279

List of Figures

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2015 63

Number of Products under Development for Non-Small Cell Lung Cancer-Comparative Analysis, H1 2015 64

Number of Products under Development by Companies, H1 2015 65

Number of Products under Investigation by Universities/Institutes, H1 2015 84

Comparative Analysis by Late Stage Development, H1 2015 88

Comparative Analysis by Clinical Stage Development, H1 2015 89

Comparative Analysis by Early Stage Products, H1 2015 90

Assessment by Monotherapy Products, H1 2015 351

Assessment by Combination Products, H1 2015 352

Number of Products by Top 10 Targets, H1 2015 353

Number of Products by Stage and Top 10 Targets, H1 2015 353

Number of Products by Top 10 Mechanism of Actions, H1 2015 375

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 375

Number of Products by Top 10 Routes of Administration, H1 2015 389

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 389

Number of Products by Top 10 Molecule Types, H1 2015 391

Number of Products by Stage and Top 10 Molecule Types, H1 2015 391

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

AB Science

AbbVie Inc.

ACEA Biosciences, Inc.

Adaptimmune Limited

Advanced Cancer Therapeutics

Advenchen Laboratories, LLC

Aeolus Pharmaceuticals, Inc.

Allinky Biopharma

Altor BioScience Corporation

Ambryx Biotechnology, Inc.

Amgen Inc.

AndroScience Corporation

Arch Biopartners, Inc.

Ariad Pharmaceuticals, Inc.

Arog Pharmaceuticals, Inc.

ArQule, Inc.

Array BioPharma Inc.

Arrien Pharmaceuticals, LLC

Ascenta Therapeutics, Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Axelar AB

Azaya Therapeutics Incorporated

Basilea Pharmaceutica AG

Bayer AG

Benitec Biopharma Limited

BerGenBio AS

Beta Pharma, Inc.

BIND Therapeutics, Inc.

BIOCAD

BioCancell Ltd

BioLineRx, Ltd.

BioNumerik Pharmaceuticals, Inc.

Biothera, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

CanBas Co., Ltd.

Cantex Pharmaceuticals, Inc.

CASI Pharmaceuticals Inc.

cCAM Biotherapeutics Ltd.

Celgene Corporation

CellAct Pharma GmbH

Celldex Therapeutics, Inc.

Cellectar Biosciences, Inc.

Cellectis S.A.

Cellmid Limited

Celltrion, Inc.

Cellular Biomedicine Group, Inc.

Centrose Llc

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co., Ltd.

Clovis Oncology, Inc.

Conkwest, Inc.

Corcept Therapeutics Incorporated

Cornerstone Pharmaceuticals, Inc.

Critical Outcome Technologies Inc.

CTI BioPharma Corp.

CureFAKtor Pharmaceuticals, LLC

CureVac GmbH

Cyclacel Pharmaceuticals, Inc.

Daiichi Sankyo Company, Limited

DanDrit Biotech A/S

Deciphera Pharmaceuticals, LLC

DEKK-TEC, Inc.

DiNonA Inc.

Domainex Limited

DormaTarg, Inc.

Eagle Pharmaceuticals, Inc.

Eisai Co., Ltd.

Eleison Pharmaceuticals, Inc.

Eli Lilly and Company

Endocyte, Inc.

EnGeneIC Ltd

EntreChem, S.L.

Epirus Biopharmaceuticals, Inc.

Eudendron S.r.l.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Fortress Biotech, Inc.

Ganymed Pharmaceuticals AG

GeneFrontier Corporation

Genelux Corporation

Genentech, Inc.

Genmab A/S

Genor BioPharma Co., Ltd.

Genosco

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Globeimmune, Inc.

GlycaNova Norway AS

Glycotope GmbH

Golden Biotechnology Corp.

Halozyme Therapeutics, Inc.

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Heat Biologics, Inc.

HEC Pharm Co., Ltd.

Helix BioPharma Corp.

Hospira, Inc.

Humanetics Corporation

Hutchison MediPharma Limited

Ignyta, Inc.

Immune Design Corp.

Immune Pharmaceuticals Inc.

ImmunGene, Inc.

ImmunoFrontier, Inc.

ImmunoGen, Inc.

Immunome Inc.

Immunomedics, Inc.

Incanthera Ltd.

Incuron, LLC

Incyte Corporation

Intezyne, Inc

Io Therapeutics, Inc.

Isis Pharmaceuticals, Inc.

Jeil Pharmaceutical Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Johnson & Johnson

Juno Therapeutics Inc.

Kadmon Corporation, LLC

KAEL-GemVax Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.

Loxo Oncology, Inc.

Mabion SA

MacroGenics, Inc.

Mebiopharm Co., Ltd.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Mersana Therapeutics, Inc.

Millennium Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

Mirna Therapeutics, Inc.

MolMed S.p.A.

Morphotek, Inc.

NanoCarrier Co., Ltd.

Natco Pharma Limited

Nektar Therapeutics

NeoPharm Co., Ltd.

NewLink Genetics Corporation

Nimbus Therapeutics, LLC

Novartis AG

NuCana BioMed Limited

Omnitura Therapeutics Inc.

Oncobiologics, Inc.

Oncogenex Pharmaceuticals, Inc.

Oncology Research International Limited

Oncolytics Biotech Inc.

OncoMed Pharmaceuticals, Inc.

Oncothyreon Inc.

Ono Pharmaceutical Co., Ltd.

Onxeo SA

Onyx Pharmaceuticals, Inc.

Optimum Therapeutics, LLC

Ora Bio Ltd.

Oscotec Inc.

OSE Pharma SA

Otsuka Holdings Co., Ltd.

Oxford BioTherapeutics Ltd

Panacea Biotec Limited

Peregrine Pharmaceuticals, Inc.

Pfizer Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

Philogen S.p.A.

Pique Therapeutics

Polaris Pharmaceuticals, Inc.

Priaxon AG

PsiOxus Therapeutics Limited

Puma Biotechnology, Inc.

Purdue Pharma L.P.

Qu Biologics Inc.

Reata Pharmaceuticals, Inc.

Recombio S.L

Regeneron Pharmaceuticals, Inc.

Rexahn Pharmaceuticals, Inc.

Samyang Holdings Corporation

Sanofi

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shionogi & Co., Ltd.

SignPath Pharma Inc

Sirnaomics, Inc.

Sotio a.s.

Spectrum Pharmaceuticals, Inc.

Sphaera Pharma Pvt. Ltd.

STELIS Biopharma Pvt. Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

Symphogen A/S

Syndax Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

Taiho Pharmaceutical Co., Ltd.

Targovax AS

TC BioPharm Limited

Teikoku Pharma USA, Inc.

Tesaro, Inc.

Teva Pharmaceutical Industries Limited

Threshold Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.

Transgene SA

Ultimovacs AS

VasGene Therapeutics, Inc.

Vaxeal Holding SA

Vaxin UK Limited

Vaxon Biotech

Verastem, Inc.

Vertex Pharmaceuticals Incorporated

VG Life Sciences, Inc.

Vichem Chemie Research Ltd.

Viralytics Ltd.

XBiotech USA, Inc.

Zhejiang BetaPharma Co., Ltd.

Zyngenia, Inc.

Non-Small Cell Lung Cancer Therapeutic Products under Development, Key Players in Non-Small Cell Lung Cancer Therapeutics, Non-Small Cell Lung Cancer Pipeline Overview, Non-Small Cell Lung Cancer Pipeline, Non-Small Cell Lung Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com